Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Raltegravir Oral Formulations in Pediatric HIV Infection
2017-000050-18Phase 2
- Sponsor
- Merck & Co.
- Start
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of raltegravir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Merck & Co. Primary endpoints: HIV RNA and safety and tolerability.
02
Drugs
raltegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2017-000050-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000050-18.